U.S. markets closed
  • S&P Futures

    3,831.50
    -7.50 (-0.20%)
     
  • Dow Futures

    31,490.00
    +25.00 (+0.08%)
     
  • Nasdaq Futures

    12,557.75
    -106.00 (-0.84%)
     
  • Russell 2000 Futures

    2,193.40
    +3.70 (+0.17%)
     
  • Crude Oil

    67.56
    +1.47 (+2.22%)
     
  • Gold

    1,703.00
    +4.50 (+0.26%)
     
  • Silver

    25.67
    +0.39 (+1.53%)
     
  • EUR/USD

    1.1906
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3819
    -0.0009 (-0.07%)
     
  • USD/JPY

    108.3850
    +0.0030 (+0.00%)
     
  • BTC-USD

    50,401.46
    +655.71 (+1.32%)
     
  • CMC Crypto 200

    1,020.32
    +77.15 (+8.18%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,800.14
    -64.18 (-0.22%)
     

Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Regeneron (REGN) closed the most recent trading day at $544.10, moving -0.75% from the previous trading session. This change lagged the S&P 500's 0.15% loss on the day. Elsewhere, the Dow lost 0.07%, while the tech-heavy Nasdaq lost 0.07%.

Investors will be hoping for strength from REGN as it approaches its next earnings release, which is expected to be February 5, 2021. The company is expected to report EPS of $8.32, up 10.93% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $2.39 billion, up 10.08% from the prior-year quarter.

Investors might also notice recent changes to analyst estimates for REGN. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. REGN is holding a Zacks Rank of #4 (Sell) right now.

Valuation is also important, so investors should note that REGN has a Forward P/E ratio of 14.23 right now. This valuation marks a discount compared to its industry's average Forward P/E of 30.99.

Investors should also note that REGN has a PEG ratio of 0.78 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.24 as of yesterday's close.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 223, putting it in the bottom 13% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research